Handelsavisen
prelaunch
Companies Healthcare 000790.SZ
00
000790.SZ Shenzhen Stock Exchange Pharmaceuticals

000790.Sz

¥4,25
Open in Charts → Attach watcher ⌖
CNY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
2,7B CNY
P/E
EV / Rev
Div yield
0,00 %
Op margin
-61,8 %
ROE
-44,8 %
Net margin
-58,7 %
Debt / equity
0,53
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the pharmaceuticals industry, primarily generating revenue through the development, production, and sale of pharmaceutical products.

Business. The company operates in the pharmaceuticals industry, primarily generating revenue through the development, production, and sale of pharmaceutical products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-44,8 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 000790.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 000790.SZ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the pharmaceuticals industry, primarily generating revenue through the development, production, and sale of pharmaceutical products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a debt-to-equity ratio of 0.53, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 0.78, suggesting potential challenges in meeting short-term obligations. The price-to-book ratio of 3.56 implies that the market values the company at a premium to its book value, while the negative return on equity of -44.77% highlights significant underperformance in generating returns for shareholders.

    Profitability metrics reveal a stark contrast to industry norms. The company reported a net loss of CNY 320.42 million, with an operating loss of CNY 337.14 million. Gross profit of CNY 252.10 million represents a margin of 46.2%, which is relatively high but insufficient to offset the operating and net losses. The return on assets of -23.07% further underscores the company's inability to generate returns from its asset base.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory risks. The absence of segment-specific data limits the ability to assess the performance of individual product lines or markets.

    The company's growth trajectory is constrained by its current financial performance. Revenue for the period was CNY 545.50 million, but the negative operating and net income suggest a lack of sustainable growth. Capital expenditures of CNY 63.04 million indicate ongoing investment, but the free cash flow of -CNY 376.70 million suggests that these investments are not yet generating positive returns. The outlook for the next fiscal year remains uncertain without significant operational improvements.

    Key risk factors include liquidity constraints and the potential for dilution. The company's net cash position is negative after accounting for total debt, which could necessitate additional financing. The risk of dilution is currently assessed as low, but the company's financial performance may change this outlook if further capital raising is required. Adjustments to the valuation have been applied to reflect these risks.

    Recent events, including financial filings and transcripts, have not provided significant new insights into the company's strategic direction or operational performance. The company's recent financial results highlight the need for cost management and operational efficiency improvements to address the current losses and improve shareholder returns.

    Key takeaways
    • The company is experiencing significant financial losses, with a net loss of CNY 320.42 million and an operating loss of CNY 337.14 million.
    • The debt-to-equity ratio of 0.53 indicates a moderate level of leverage, but the current ratio of 0.78 suggests liquidity concerns.
    • The company's return on equity of -44.77% and return on assets of -23.07% highlight poor performance in generating returns.
    • The company's revenue is concentrated in a single segment, increasing exposure to regional and regulatory risks.
    • The company's free cash flow is negative at -CNY 376.70 million, indicating that operations are not generating sufficient cash to fund investments.
    • The risk of dilution is currently low, but the company's financial performance may necessitate additional financing in the future.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥4,25
    Market cap
    ¥2.54B
    Enterprise value
    ¥2.92B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    34.2x
    P / B
    3.6x
    P / Tangible book
    3.6x
    Tangible book
    ¥715.7M
    Net cash
    -¥379.0M
    Current ratio
    0.8
    Debt / equity
    0.5
    ROA
    -23.1%
    ROE
    -44.8%
    Cash conversion
    -27.0%
    CapEx / revenue
    -11.6%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-61,8 %Bottom quartile
    Net Margin-58,7 %Bottom quartile
    ROE-44,8 %Bottom quartile
    Capex / Rev-11,6 %Below median
    D/E0,53Below median
    Cash Conv-0,27Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • 000790.SZ Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    000790.SZCanonical
    Shenzhen Stock Exchange · CNY

    Intel & risk

    What changed

    4 tracked-field change(s) detected vs prior analysis; max severity: medium.

    • Dilution risk— → lowlow
    • Liquidity risk— → mediumlow
    • Activity— → Pharmaceuticalsmedium
    • Economic sector— → Healthcaremedium
    vs prior analysis today
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage